Re: What's the deal with Zenith?
in response to
by
posted on
Jun 24, 2023 02:29PM
Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials
IMHO, anything DM says at AGM is just trying to get some excitement as a saleman which he is.
If any BP deal whether a royalty deal, license, or partnership does occur in 2023 it will come out of the nowhere . The more quiet Zenith is the better. If there was a non binding term sheet on a royalty deal for Zenith than he could talked about it at the AGM. So imo it just an ideal at this point or ,maybe a few meeting with pharma discussing it . Rumours are just rumours until they are not....